tacrine has been researched along with Amyotrophic Lateral Sclerosis in 3 studies
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.
tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics of 9-amino-1,2,3,4-tetrahydroacridine; tacrine, THA, was studied after intravenous administration and following the first and last oral doses of a seven week clinical trial involving 8 patients with amyotrophic lateral sclerosis, ALS." | 3.68 | Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. ( Aquilonius, SM; Askmark, H; Hartvig, P; Lindström, B; Wiklund, L, 1990) |
| " There were no consistent pharmacokinetic differences that could explain the effect on intravenous THA on muscle strength in these two patients." | 2.67 | Functional and pharmacokinetic studies of tetrahydroaminoacridine in patients with amyotrophic lateral sclerosis. ( Aquilonius, SM; Askmark, H; Gillberg, PG; Hartvig, P; Hilton-Brown, P; Lindström, B; Nilsson, D; Stålberg, E; Winkler, T, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maloteaux, JM | 1 |
| Askmark, H | 2 |
| Aquilonius, SM | 2 |
| Gillberg, PG | 1 |
| Hartvig, P | 2 |
| Hilton-Brown, P | 1 |
| Lindström, B | 2 |
| Nilsson, D | 1 |
| Stålberg, E | 1 |
| Winkler, T | 1 |
| Wiklund, L | 1 |
1 trial available for tacrine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Functional and pharmacokinetic studies of tetrahydroaminoacridine in patients with amyotrophic lateral sclerosis.
Topics: Administration, Oral; Adult; Aged; Amyotrophic Lateral Sclerosis; Drug Therapy, Combination; Electro | 1990 |
2 other studies available for tacrine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
[Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases].
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cholinesterase Inhibitors; H | 1996 |
Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine.
Topics: Administration, Oral; Adult; Aged; Aminoacridines; Amyotrophic Lateral Sclerosis; Biological Availab | 1990 |